Gland Pharma Limited submitted an investor presentation detailing its Q2 FY27 financial results to BSE Limited and the National Stock Exchange of India Limited, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance (Consolidated)

Profit & Loss Statement (₹ Mn):

  • Revenue from operations: ₹18,336 in Q2 FY27 (vs. ₹14,869 in Q2 FY26; +23% YoY) and ₹36,339 for 6M FY27 (vs. ₹29,925 in 6M FY26; +21% YoY)
  • Other Income: ₹690 in Q2 FY27 (vs. ₹842 in Q2 FY26; -18% YoY)
  • Total Income: ₹19,026 in Q2 FY27 (vs. ₹15,710 in Q2 FY26; +21% YoY)
  • Gross Profit: ₹11,638 in Q2 FY27 (vs. ₹9,331 in Q2 FY26; +25% YoY); Gross Profit margin stable at 63%
  • EBITDA: ₹4,804 in Q2 FY27 (vs. ₹3,139 in Q2 FY26; +53% YoY); EBITDA margin at 26% (vs. 21%)
  • Adj. EBITDA: ₹5,030 in Q2 FY27 (vs. ₹3,355 in Q2 FY26; +50% YoY); Adj. EBITDA margin at 27% (vs. 23%)
  • PBT: ₹4,309 in Q2 FY27 (vs. ₹2,839 in Q2 FY26; +52% YoY); PBT margin at 24% (vs. 19%)
  • PAT: ₹2,908 in Q2 FY27 (vs. ₹1,837 in Q2 FY26; +58% YoY); PAT margin at 16% (vs. 12%)

Business Performance

Revenue Break-up by Business (₹ Mn):

  • CDMO Business: ₹8,227 in Q2 FY27 (vs. ₹6,289 in Q2 FY26; +31% YoY)
  • Critical Injectables: ₹10,109 in Q2 FY27 (vs. ₹8,580 in Q2 FY26; +18% YoY)
  • Total Revenue: ₹18,336 in Q2 FY27 (vs. ₹14,869 in Q2 FY26; +23% YoY)

Geographical Revenue:

  • US Market: Growth driven by recent CDMO product launches (Dalbavancin and Multi-Vitamin) and Critical Injectables new launch (Sugammadex) and volume expansion in existing products.
  • Europe Market: Contributed 20% of Q2 FY27 revenue; growth driven by CDMO launches (Dalbavancin) and volume expansion (Daptomycin).
  • Other Core Markets (Canada, Australia, New Zealand): Revenue declined due to volume decline in existing products.
  • Rest of the World: Contributed 11% of Q2 FY27 revenue; growth impacted by lower volumes due to delayed tender business in the Middle East.
  • India: Contributed 2% of Q2 FY27 revenue; growth impacted by lower volume uptake.

Operational and Strategic Updates

  • R&D Expenses: ₹1,077 million in Q2 FY27 (6% of consolidated revenue), focused on complex product development and filings.
  • New Launches: Launched 4 molecules in the USA: Sugammadex, Erythromycin, Fluorouracil, and Atropine sulfate.
  • Filings and Approvals: Filed 11 ANDAs and received 10 approvals in Q2 FY27; cumulative ANDA filings reached 399 (350 approved, 49 pending).
  • In-house Complex Pipeline: Six products launched; three more in line for approval.
  • Co-development Partnerships: Fifteen products in co-development (seven 505(b)(2) and eight ANDAs); commercialization expected to begin in FY29.
  • Ready-to-Use (RTU) Bags: Filed 24 products, received approval for 18; 8 more under development; total portfolio addresses a US market opportunity of approximately $640 million.
  • CDMO Partnership: Technology transfer activities with a global pharmaceutical company advancing as planned; partnership expanded with additional technology transfer dossiers.
  • Strategic CDMO Collaborations: Secured manufacturing contracts for microspheres and respiratory products.
  • Quality and Compliance: Two facilities audited by USFDA; VSEZ had zero observations, Dundigal concluded with four procedural observations (October 2026).

Additional Financial Metrics

  • 6M FY27 Performance: Revenue ₹36,339 Mn (+21% YoY), PAT ₹6,077 Mn (+52% YoY)
  • Definitions Provided:
  • Gross Profit = Revenue from Operations – Materials consumed
  • EBITDA = Profit before tax plus finance expense plus depreciation and amortization expense, excluding other income and forex losses
  • Adj. EBITDA = EBITDA plus Employee stock option compensation expenses and one-off GST-related provision